Prosight Management’s ADC Therapeutics ADCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $28.1M | Buy |
10,467,771
+924,767
| +10% | +$2.48M | 6.84% | 4 |
|
|
2025
Q1 | $13.5M | Buy |
9,543,004
+28,004
| +0.3% | +$39.5K | 4.42% | 8 |
|
|
2024
Q4 | $18.9M | Sell |
9,515,000
-121,237
| -1% | -$241K | 5.23% | 6 |
|
|
2024
Q3 | $30.4M | Buy |
9,636,237
+66,237
| +0.7% | +$209K | 7.47% | 1 |
|
|
2024
Q2 | $30.2M | Buy |
9,570,000
+2,519,700
| +36% | +$7.96M | 9.04% | 2 |
|
|
2024
Q1 | $31.7M | Buy |
7,050,300
+578,500
| +9% | +$2.6M | 8.81% | 2 |
|
|
2023
Q4 | $10.7M | Buy |
6,471,800
+1,069,759
| +20% | +$1.78M | 4.31% | 8 |
|
|
2023
Q3 | $4.85M | Sell |
5,402,041
-181,859
| -3% | -$163K | 1.54% | 22 |
|
|
2023
Q2 | $12M | Buy |
5,583,900
+2,326,540
| +71% | +$5M | 3.51% | 12 |
|
|
2023
Q1 | $6.35M | Buy |
3,257,360
+2,794,050
| +603% | +$5.45M | 3.01% | 13 |
|
|
2022
Q4 | $1.78M | Buy |
463,310
+215,680
| +87% | +$828K | 0.97% | 25 |
|
|
2022
Q3 | $1.19M | Buy |
+247,630
| New | +$1.19M | 0.64% | 30 |
|